Hubble Therapeutics Secures $7.3 Million Series A for Groundbreaking Gene Therapy

Hubble Therapeutics LLC, a biotechnology company focused on patient-centered gene therapy, has successfully concluded a Series A funding round worth $7.3 million. This critical funding supports the advancement of their lead candidate, HUB-101, into human clinical trials. HUB-101 is a gene therapy targeting Leber congenital amaurosis type 16 (ACL16) and Snowflake Vitreoretinal Degeneration (SVD), two severe retinal dystrophies caused by mutations in the KCNJ13 gene. These conditions, which typically manifest in children under five, lead to progressive blindness. The gene therapy, developed by Dr. Bikash Pattnaik from the University of Wisconsin-Madison and licensed through the Wisconsin Alumni Research Foundation, aims to correct the ion channel dysfunction at the disease’s root. Hubble Therapeutics partners with Andelyn Biosciences and Virscio for the development and regulatory submission of HUB-101, which has received rare pediatric disease and orphan disease designation from the FDA. With plans to enter Phase I/II clinical trials by 2026, the efforts of Dr. Pattnaik and Hubble Therapeutics highlight the transformative potential of industry-academic partnerships in creating innovative treatments for genetic conditions.